GERN

0.87074.63%
DC

Dawn Carter Bir

Independent Director

Ms. Dawn Carter Bir is an Independent Director of Filana Therapeutics, Inc. (formerly known as Cassava Sciences, Inc.) from October 2025. Ms. Bir is a Director at Soleno Therapeutics, Inc. since August 12, 2024. She was Chief Commercial Officer of Reata Pharmaceuticals, Inc. since September 2016 and oversee marketing, market access, sales, training and commercial operations. Ms. Bir joined Reata Pharmaceuticals with over many years of biopharmaceutical sales and marketing experience. Ms. Bir serves as Executive Vice President at Reata Pharmaceuticals, Inc. since 2018 and was its Vice President since September 2016. Over the past decade she served in senior leadership roles at Pharmacyclics, LLC, McKesson Corporation and Genentech, Inc. Prior to joining Reata, Ms. Bir served as Vice President of US Sales at Pharmacyclics, LLC. From February 2013 to September 2016, she built and led their first hematology national sales organization of sales Representatives, division Managers and regional sales Directors, responsible for the launch of IMBRUVICA? in the US and Puerto Rico. In only 18 months, her team became an industry recognized commercial sales presence and executed a history making oncology launch. Prior to joining Pharmacyclics, LLC, she served as Vice President of Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals and RxPak from October 2011 to February 2013. She serves as a member of the board of directors of Geron Corporation and served as its Interim President & CEO since March 11, 2025 until August 7, 2025. She held positions of increasing responsibility within McKesson Corporation, Genentech, Inc. and Bristol Myers Squibb Company. Ms. Bir received a B.S. in Biology from Binghamton University, Binghamton, NY.

Positions